BRIEF—Healx raises $56 million in series B round

Cambridge, UK-based drug discovery firm Healx has raised $56 million in a series B financing round, led by one of Europe’s largest VC firms, Atomico.

The money will be used to develop the company’s therapeutic pipeline and to launch a global “Rare Treatment Accelerator” program, a collaboration for select rare disease patient groups which aims to leverage artificial intelligence to advance treatments.

Chief executive Tim Guilliams said: “The size of this series B financing, especially this quickly after our series A round last year, is an endorsement of the value of our platform and the pace at which we have developed.”